Randomized Phase II trial of Cyclophosphamide and the Oral Poly (ADP-ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer

BACKGROUND: In tumors carrying BRCA mutations, DNA damage caused by standard cytotoxic chemotherapy can be potentiated by poly [ADP-ribose] polymerase (PARP) inhibitors, leading to increased cell death through synthetic lethality. Individuals carrying mutations in BRCA have an increased incidence of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Autores principales: Kummar, Shivaani, Wade, James L., Oza, Amit M., Sullivan, Daniel, Chen, Alice P., Gandara, David R., Ji, Jiuping, Kinders, Robert J., Wang, Lihua, Allen, Deborah, Coyne, Geraldine O’Sullivan, Steinberg, Seth M., Doroshow, James H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4860030/
https://ncbi.nlm.nih.gov/pubmed/26996385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0335-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares